Although maximal cytoreduction is the cornerstone of current treatment for patients with advanced ovarian cancer, optimal cytoreduction is not always achievable in the clinic. Therefore, using clinical characteristics, diagnostic imaging, serum biomarkers or laparoscopic findings, many studies have attemptesd to find models for predicting surgical resectability. However, most of these prediction models showed limited effectiveness and have not been properly validated. To establish a reliable prediction model, several requirements should be met. First, the goal of surgical cytoreduction should be adequately defined. Second, the desired accuracy for making the model clinically useful should be defined. Third, the model should test all relevant predictors, including clinical, radiological and biochemical predictors, and be developed using a large dataset that provides a sufficient number of events. Fourth, any prediction model should be validated with a relevant external dataset. Lastly, the prediction model should be able to aid decision making and, thereby, improve the outcome of patients. Therefore, randomized clinical trials with decision making based on prediction models are urgently required.
introduction
Ovarian cancer is the leading cause of gynecologic cancer death in Western countries [1] . At least two-thirds of women who are diagnosed with ovarian cancer have advanced disease at the time of diagnosis. Currently, the standard treatment for these patients is maximal cytoreductive surgery followed by platinum-based systemic chemotherapy [2] . After Griffiths reported that cytoreduction to <1.5 cm in size is an important prognostic factor [3] , gynecologic oncologists have struggled to achieve a higher rate of optimal cytoreduction. The cut-off for determining optimal cytoreduction has been changed repeatedly [4] [5] [6] [7] and a residual tumor size of <1 cm is now generally accepted as the definition of optimal surgical cytoreduction [7] .
However, despite maximal surgical effort, optimal cytoreduction is not always possible in patients with advanced disease [8, 9] . Therefore, many studies have attempted to develop a model to predict the possibility of optimal cytoreduction, using various clinical characteristics, diagnostic imaging, laparoscopic findings and biomarkers such as CA125 [10] . However, none of these models has successfully elicited a consensus in the clinical community and many gynecologic oncologists remain skeptical about the feasibility of preoperative prediction of optimal cytoreduction [11] . Why have so many studies failed to convince gynecologic oncologists to use their prediction tools in the clinic? Why are gynecologic oncologists reluctant to use these proposed prediction tools in their practice?
reference standard: how should the term 'optimal' be defined?
First, the concept of optimal cytoreduction has not been clarified, which introduces significant confusion in developing a prediction model of optimal cytoreduction. In the early studies that sought to predict the surgical resectability of ovarian cancer, optimal cytoreduction was defined as a residual tumor of <2.0 cm in diameter [12, 13] . However, recently, most studies define optimal cytoreduction as a residual tumor of <1.0 cm [14, 15] . Moreover, many experts now claim that not 1.0 cm, but complete resection, i.e. the absence of a gross residual tumor, should be the goal of the surgical management of ovarian cancer [6, 16, 17] . In a recent exploratory analysis of three prospective randomized trials (AGO-OVAR 3, 5 and 7), du Bois et al. reported that the overall survival of advanced ovarian cancer patients significantly differed between those without a gross residual tumor and patients with a residual tumor of <1.0 cm [17] . On the other hand, the authors observed that the impact of debulking the residual tumor to <1.0 cm was very small. The patients with residual tumors of >1.0 cm showed a hazard ratio of 1.2 compared with patients with residual tumors of 1-10 mm. Thus, considering the impact on survival outcome, it would be more appropriate to define optimal cytoreduction as the complete absence of a gross residual tumor. The cut-off that defines the 'optimal' size of the residual tumor in prediction models may not only determine the design and symposium article [18] . However, indicators such as sensitivity or specificity are not highly intuitive and clinicians may therefore find it difficult to understand the clinical usefulness of a model based on these indicators. Thus, many studies frequently transform these indicators into LRs or diagnostic odds ratios [19, 20] . A positive LR can be calculated using the following formula: sensitivity / (1 2 specificity). A positive LR is defined as the probability of positive test results among patients with events divided by the probability of positive test results among patients without events. Usually, a positive LR >5.0 indicates that the test is useful for predicting positive outcomes [21, 22] . Conversely, a negative LR can be calculated using the formula: (1 2 sensitivity) / specificity. Similarly, a negative LR <0.2 indicates that the test can be applied for excluding negative outcome [21, 22] . In Table 1 , the sensitivity and specificity of various studies investigating the performance of computed tomography (CT) imaging in predicting surgical resectability were transformed into positive and negative LRs [12, 13, 15, [23] [24] [25] [26] [27] [28] . Six of the nine studies resulted in a positive LR >5.0, suggesting that many studies have reported CT imaging to be useful for identifying patients with a high risk of suboptimal cytoreduction. Two studies showed high positive LRs and low negative LRs, suggesting that the overall performance of these models may be strong. Thus, any prediction model for surgical resectability should be evaluated by performance indicators resistant to variability in event prevalence.
accuracy: how accurate is accurate enough?
It should be noted that many prognostic studies in the cancerresearch field based on a multivariate modeling approach yield area under the ROC curve values of 0.60-0.80 [29] [30] [31] . This trend implies that it may be difficult to establish a model that can predict optimal cytoreduction with high accuracy. Surgeons with higher surgical capability and the support of a multidisciplinary team can achieve successful cytoreduction, with <1 cm of the residual tumor remaining in 80%-90% of their patients [32] . In this case, the surgeon would not use a prediction model with such accuracy, because assessing all patients as 'resectable' would yield a higher accuracy than referring to a prediction model. Therefore, we should be aware that the accuracy of a prediction model may be limited because optimal cytoreduction is not an outcome that can be determined simply by a few covariates. As addressed by Bristow et al., predicting surgical resectability may be akin to 'taking aim at a moving target' [33] and accurate preoperative prediction may not be possible. Notably, it was reported that prediction accuracy might only reach 75%, even with the use of an invasive procedure such as laparoscopy and observation of the state of the intraperitoneal cavity [34] . Therefore, it may be reasonable to shift the paradigm from prediction to risk assessment through a grouping strategy. Namely, with a risk-grouping model, patients can be classified as high or low risk for optimal cytoreduction. For example, a surgeon dedicated to extensive surgery in a high-volume hospital may achieve a high rate of optimal cytoreduction in the group classified as high risk by a risk model. However, in that case, the high rate of optimal cytoreduction may represent not the inaccuracy of the risk model, but the excellent surgical capabilities of the surgeon and institution. In addition, the 'risk-grouping' concept may be useful for designing clinical trials testing a proper triage for a high-risk group. Given these factors, how accurate should a risk model be to be accepted as clinically useful? A recent study suggested a few models based on clinical data, serum CA125 and diagnostic imaging [24] .
The authors reported that their models showed area under the curve (AUC) ranging from 0.78 to 0.82. Another recent study of a scoring system based on laparoscopic findings showed an AUC of 0.74 [39] . Therefore, considering these recent reports, we suggest that any future prediction model should aim to achieve an AUC >0.75. Many of the studies on surgical resectability had small numbers of subjects and thus had a very limited number of events. When the size of the dataset is limited, the number of candidate predictors that can be reliably tested in a multivariate analysis is also limited. A well-known rule of thumb is the 1-in-10 rule, i.e. 1 candidate predictor can be studied for every 10 events [35, 36] . For example, for 30 patients who underwent suboptimal cytoreduction in a study of 100 patients, only 3 candidate predictors could reliably be tested. However, this rule has been frequently violated in studies on prediction models for surgical resectability, especially in studies testing too many image-based predictors. If the rule is violated, the number of candidate predictors is too large for the dataset and overfitting is likely to occur. This issue subsequently results in a situation where a model that performed well in the original dataset poorly reproduces in an independent dataset. A recent study analyzed medical data and CT images of 65 patients, and the event, i.e. suboptimal cytoreduction, was observed only in 14 out of 65 patients in the study [25] . The authors selected two predictors: diaphragmatic disease and mesenteric involvement.
They achieved an accuracy of 77% by combining these two predictors into the model. However, if we look at the dataset, we can easily see that the authors would achieve the same accuracy if they selected only one of the two predictors while following 1 : 10 rule. The model reproduced poorly in external datasets, which may have been a consequence of overfitting. Therefore, it is crucial to reduce the risk of overfitting in the development stage of a risk model. In this context, we have some concerns about risk assessment using laparoscopy. In general, it is likely that an overestimation of surgical outcome may be introduced when a surgeon is informed of the test results before surgery. Thus, many risk assessments using laparoscopy may be constrained by concerns about overestimation of their performance.
generalizability: the importance of external validation
Many clinicians could be reluctant to adopt a prediction model derived from one specific population or institution, because of a generalizability issue. Thus, adequate validation of a model in an independent external dataset is very important to minimize the risk of overoptimism. Axtell et al. sought to investigate the diagnostic performance of their own prediction model in two independent cohorts [25] . In addition, they tested the diagnostic performances of two other previously developed models based on CT predictors in their cohort. The authors found that the performance of the tested models reproduced poorly in the independent dataset. Performance discrepancies among different institutions have also been observed in many studies testing the predictive performance of serum CA125 [37] . In a previous meta-analysis reported by Kang et al., the predictive ability of CA125 >500 IU/ml to predict optimal cytoreduction varied among institutions. Moreover, two studies from the same institution but at a different time and under different surgical policies resulted in different predictive performances [14, 38] . However, there is a model that showed a similar performance in an external validation. Based on laparoscopy findings, Fagotti et al. derived a prediction scoring system with an overall accuracy of 75% [34] . Unlike the validation study of various imaging models, the accuracy of the laparoscopy-based model was similarly reproduced in an independent patient set [39] , suggesting that developing a generalizable model for resectability is not an unachievable goal.
what factors should be considered?
To convince clinicians of the credibility of a prediction model, it is important that all clinically relevant patient data have been tested for inclusion in the model. Factors used to predict surgical resectability might include clinical characteristics of the patients, the extent and size of the tumor in diagnostic imaging, serum levels of biomarkers, or the results of direct visual examination by laparoscopy. First, it may be wise to include and test the age of patients and performance status as predictors, although the relationship between these parameters and optimal cytoreduction is debatable [24, 28, 40] . There has been little evidence suggesting that certain histologic types are associated with the difficulty of cytoreductive surgery. However, one study suggested that some minor histologic types were more likely to be completely removed than a serous type [41, 42] . The most important predictors may be various indicators of the anatomic spread, extent and size of the tumor. Usually, these parameters are investigated as a form of imaging data. Among the many predictors that have been suggested, a few commonly suggested predictors are listed here: diaphragmatic disease [15, [23] [24] [25] , a large volume of ascites [15, 23, 27] , disease involving the mesentery [15, 24, 25] and diffuse peritoneal thickening or implants [15, 27] . Although some of these factors could merely be correlated with other predictors rather than true predictors, each of these predictors should be thoroughly tested when attempting to establish a prediction model. Another tool for assessing the risk of suboptimal cytoreduction may be direct visual examination via laparoscopy. Because the accuracy of diagnostic imaging is not perfect, some researchers have attempted to develop a scoring system based on laparoscopic findings. Fagotti et al. designed a scoring system consisting of eight parameters [34] . Although it can be conceded that laparoscopy may be the most accurate prediction tool, it is questionable whether a clinical decision-making process based on such an invasive procedure would result in more benefits than costs, including the risk of port-site metastasis [43] . Lastly, serum biomarkers, such as CA125, can be used to predict resectability. Predicting resectability based on CA125 was first suggested by Chi et al. [14] and led many researchers to investigate the hypothesis in their own patient populations [27, 38, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . Kang et al. summarized these results in a recent meta-analysis and concluded that serum CA125 has a sensitivity of 69% and specificity of 63% at a cut-off of 500 IU/ml [37] . Although a serum CA125 level >500 IU/ml is a strong risk factor of suboptimal cytoreduction (odds ratio = 3.7), the biomarker alone was not useful for the prediction of optimal cytoreduction. Therefore, the ideal method for establishing a risk model may be to test all the above candidate parameters Annals of Oncology symposium article in a sufficiently sized patient cohort that can provide a sufficient number of events to identify all the relevant predictors.
integration of surgeon factor into a prediction model
It is well known that the surgeon factor plays an important role in the determination of optimal cytoreduction [40, 58] . Indeed, several high-volume institutions with a dedicated surgeon and multidisciplinary team frequently report an excellent rate of optimal cytoreduction [32] . However, in most prediction models, the surgeon factor is usually not considered during model development. It is evident that the exclusion of the surgeon factor can be an obstacle to the reproducibility of a model in an independent dataset. Thus, quantitative indicators representing the surgeon's capability, dedication and attitude, and the institution's resources should be provided in the future. One example of this approach is the scoring system developed to estimate the complexity of surgery by Aletti et al [59] . This scoring system was originally developed for quality assessment of ovarian cancer surgery, but it has been suggested that this score may also be associated with cytoreduction outcome [58] . This correlation is relevant, because the score represents the surgical effort of the surgeon. However, the score does not represent the capability or the quality of the multidisciplinary surgical team. Thus, more informative indicators should be developed in the future.
clinical effectiveness: why should we have to predict?
Even assuming that we can obtain an accurate and credible method to predict the feasibility of optimal cytoreduction in advanced ovarian cancer, the most important step remains: convincing clinicians of the usefulness of the prediction model. Clinical trials are vital for evaluating the safety and efficacy of a model. Thus, the absence of reliable clinical trials supporting the use of a prediction model may the most important reason why many clinicians reject the use of the model in their clinical practice. Thus, prediction models for optimal cytoreduction should be tested as to whether clinical decision making based on the model can improve patient outcome.
To design such trials we should have a relevant hypothesis of clinical decision making based on a prediction model. Therefore, what kind of medical decision can be made? If a patient is determined to be unresectable, what alternative treatment is there to improve her outcome? While investigating models for predicting optimal cytoreduction, many researchers hoped that neoadjuvant chemotherapy could be a valid alternative for patients classified as unresectable [60] . This assumption was based on a number of observations that neoadjuvant chemotherapy significantly increased the rate of optimal cytoreduction [61] , which is the most important prognostic factor in advanced ovarian cancer. However, unfortunately, a recent randomized trial reported that the increased rate of optimal cytoreduction did not translate into increased survival gain [62] . More importantly, the randomized trial failed to show that neoadjuvant chemotherapy was beneficial in any risk group. In addition, the randomized trial did not demonstrate an advantage of neoadjuvant chemotherapy in terms of adverse effects, postoperative morbidity or quality of life, as a statistical comparison was not attempted in the trial due to the divergent characteristics of the two arms. Therefore, it is still unclear whether neoadjuvant chemotherapy is an effective alternative for patients with a low chance of optimal cytoreduction.
However, there remains a possibility that neoadjuvant chemotherapy may be beneficial in a subgroup with high probability of successful cytoreduction. A recent retrospective study by Kang et al. showed that neoadjuvant chemotherapy increased survival benefit in the subgroup with CA125 levels >2000 IU/ml, which represents a high tumor burden and extent of spread [63] . Although only a hypothesis-generating study, this study can provide a paradigm for future trials to test the effectiveness of neoadjuvant chemotherapy based on a prediction model of resectability. Thus, future trials should aim to test whether a decision-making process using prediction of resectability can help enhance the outcome of patients with ovarian cancer.
In addition, some studies support the routine or liberal use of neoadjuvant chemotherapy in the management of advanced ovarian cancer [64] [65] [66] [67] . This viewpoint is based on evidence that survival with neoadjuvant chemotherapy is not inferior to that associated with primary surgery [61, 62] . However, this viewpoint also raises the dilemma of whether risk assessment for suboptimal cytoreduction should be performed. If a treatment has a survival outcome that is similar to a standard treatment but likely to offer reduced morbidity, decreased blood loss and shorter hospital stays, why should we make an effort to classify a group of patients who are suitable for the standard treatment rather than using this alternative treatment liberally? In this context, predicting surgical resectability may not influence the decision of either advocates or opponents of neoadjuvant chemotherapy. Therefore, not only do we currently lack a reliable tool for assessing the surgical resectability of ovarian cancer, but we also do not have a rationale for tailoring a patient's treatment according to the predicted resectability.
Although it is unclear whether current prediction models are useful in clinical decision making in terms of survival benefit or operative morbidity, it may help to anticipate the complexity of surgery and the need to perform extensive surgery to achieve optimal residual disease [38] . Therefore, whether a prediction model of resectability may aid the decision to transfer patients to a high-volume cancer center [68] [69] [70] [71] and thereby enhance the survival of ovarian cancer patients should be evaluated further.
conclusions
Maximal cytoreductive surgery is the cornerstone of treatment for advanced ovarian cancer. However, it is also true that some patients have unfavorable risk factors indicating difficult optimal surgery. Although we do not have any evidence that clinical decision making based on the prediction of surgical resectability can improve patient outcome, a relevant risk model is required to assess patient risk, compare study populations and design clinical trials for triage. For this purpose, first, a consensus should be reached regarding the goal of surgical cytoreduction. Second, the optimal accuracy of the model should be defined. Third, the model should test all relevant predictors and be developed using a sufficiently large dataset providing enough events. Fourth, for external validation, any prediction model should provide reproducibility in a relevant external dataset outside the institution where the model was initially developed. Fifth, the prediction model should be tested as to whether it can aid decision making and improve patient outcome, including quality of life or morbidity. Any appropriate hypothesis should be suggested and robustly discussed within the community of gynecologic oncologists. In addition, these hypotheses should be tested in well-designed, randomized controlled trials. To achieve these goals, communication and cooperation among international oncologic study groups are necessary.
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